Literature DB >> 8291902

Chemical pathology of homocysteine. I. Atherogenesis.

K S McCully1.   

Abstract

The atherogenic properties of homocysteine were discovered by observation of arteriosclerosis in children with homocystinuria caused by inherited deficiency of three different enzymes. Hyperhomocysteinemia is generally recognized as an independent risk factor for coronary, cerebral, and peripheral atherosclerosis. Hyperhomocysteinemia is caused by heterozygosity for homocystinuria, micronutrient deficiency from dietary imbalance, toxins, drugs, hormones, and other factors, explaining many key observations concerning the epidemiology of atherosclerosis. The etiological factors for atherosclerosis are believed to increase conversion of methionine to homocysteine thiolactone, the reactive cyclic internal lactone of homocysteine. The free amino groups of low density lipoprotein (LDL) are thiolated by homocysteine thiolactone, causing aggregation and increased uptake of LDL by macrophages, explaining lipid deposition in atheromas. Homocysteine thiolactone, released from homocysteinylated LDL within vascular wall, promotes intimal injury, oxidation of cholesterol and unsaturated lipids, platelet aggregation, thrombogenic factors, myointimal hyperplasia, deposition of sulfated glycosaminoglycans, fibrosis and calcification of atherosclerotic plaques.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8291902

Source DB:  PubMed          Journal:  Ann Clin Lab Sci        ISSN: 0091-7370            Impact factor:   1.256


  19 in total

Review 1.  Platelet PlA2 polymorphism and thromboembolic events: from inherited risk to pharmacogenetics.

Authors:  P J Goldschmidt-Clermont; C M Roos; G E Cooke
Journal:  J Thromb Thrombolysis       Date:  1999-08       Impact factor: 2.300

2.  Autoantibodies to folate receptor during pregnancy and neural tube defect risk.

Authors:  Robert M Cabrera; Gary M Shaw; Johnathan L Ballard; Suzan L Carmichael; Wei Yang; Edward J Lammer; Richard H Finnell
Journal:  J Reprod Immunol       Date:  2008-09-18       Impact factor: 4.054

3.  Neonatal atypical hemolytic uremic syndrome due to methylmalonic aciduria and homocystinuria.

Authors:  Francesca Menni; Sara Testa; Sophie Guez; Gabriella Chiarelli; Luisella Alberti; Susanna Esposito
Journal:  Pediatr Nephrol       Date:  2012-03-25       Impact factor: 3.714

4.  The effect of in vitro homocystinuria on the suckling rat hippocampal acetylcholinesterase.

Authors:  Kleopatra H Schulpis; Konstantinos Kalimeris; Constantinos Bakogiannis; Theodore Tsakiris; Stylianos Tsakiris
Journal:  Metab Brain Dis       Date:  2006-05-06       Impact factor: 3.584

5.  Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder.

Authors:  Ajay P Sharma; Cheryl R Greenberg; Asuri N Prasad; Chitra Prasad
Journal:  Pediatr Nephrol       Date:  2007-09-14       Impact factor: 3.714

6.  Hyperhomocysteinemia exacerbates the development of intimal hyperplasia in Sprague-Dawley rats: Alleviation by rosiglitazone.

Authors:  Sn Murthy; Va Fonseca; Db McNamara
Journal:  Exp Clin Cardiol       Date:  2005

7.  Hyperhomocysteinemia: An emerging risk factor for cardiovascular disease.

Authors:  V Govindaraju; C N Manjunath; H Venkataramiah; T R Raghu
Journal:  Indian J Clin Biochem       Date:  2003-01

8.  Hydrogen sulfide ameliorates hyperhomocysteinemia-associated chronic renal failure.

Authors:  Utpal Sen; Poulami Basu; Oluwasegun A Abe; Srikanth Givvimani; Neetu Tyagi; Naira Metreveli; Karan S Shah; John C Passmore; Suresh C Tyagi
Journal:  Am J Physiol Renal Physiol       Date:  2009-05-27

Review 9.  Biomarkers in Diabetic Retinopathy.

Authors:  Alicia J Jenkins; Mugdha V Joglekar; Anandwardhan A Hardikar; Anthony C Keech; David N O'Neal; Andrzej S Januszewski
Journal:  Rev Diabet Stud       Date:  2015-08-10

10.  MTHFR gene C677T and A1298C polymorphisms and homocysteine levels in primary open angle and primary closed angle glaucoma.

Authors:  Shazia Micheal; Raheel Qamar; Farah Akhtar; Muhammad Imran Khan; Wajid Ali Khan; Asifa Ahmed
Journal:  Mol Vis       Date:  2009-11-09       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.